An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS in Patients With Moderate to Severe Scalp Psoriasis

Trial Profile

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS in Patients With Moderate to Severe Scalp Psoriasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2017

At a glance

  • Drugs Desoximetasone (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 16 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2018.
    • 17 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top